Abstract
The challenges with modeling the spread of Covid-19 are its power-type growth during the middle stages with the exponents depending on time, and the saturations mainly due to the protective measures, though weakening and partial destruction of the virus due to mutations is a consideration too. The two-phase solution we propose for the total number of detected cases of Covid-19 describes the actual curves in many countries almost with the accuracy of physics laws. Bessel functions play the key role in our approach. The differential equations we obtain are of universal type; they describe momentum risk-management in behavioral psychology, transient processes in invasion ecology, etc. Due to a very small number of parameters, namely, the initial transmission rate and the intensity of the hard and soft measures, we obtain a convincing explanation of the surprising uniformity of the spread in many different areas. This theory can be used for forecasting the epidemic spread, evaluating the efficiency of the protective measures and the vaccinations. For instance, the early projection for the 3rd wave in the USA was very exact. The data until summer 2021 for India, South Africa and UK are discussed.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
none
Funding Statement
We acknowledge support by NSF grant DMS-1901796 and the Simons Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated data until August 08, 2021 for Covid-19 in South Africa, and UK.
Data Availability
“A surprising formula for the spread of Covid-19 under aggressive management”, MedRxiv, doi: 10.1101/2020.04.29.2008448 , 2020.
https://www.medrxiv.org/content/10.1101/2020.11.20.20235903v2
